for Tardive Dyskinesia in Adults

HELP GAIN CONTROL OF TD MOVEMENTS1

>70%

of adults experienced a
reduction in td movements2,3,*

*In a 12-week clinical study, people taking AUSTEDO had at least a 10% reduction based on the total motor Abnormal Involuntary Movement Scale (AIMS) score at Week 12.1

AUSTEDO XR can

reduce td
movements in
some
as early as 2 weeks1

AUSTEDO XR can be taken with

most mental health medications1,3,4

96%

of patients continued taking AUSTEDO XR without needing to reduce their dose due to side effects1

AUSTEDO XR delivered
consistent movement improvement and established
safety results in a 3-year study.5,6,†

This was an open-label study, which is a drug
trial in which all participants are
aware of the drug
being tested.

ask your doctor

if austedo xr

is right for you

Once-daily AUSTEDO XR contains the same active ingredient as twice-daily AUSTEDO® (deutetrabenazine) tablets. Data on this page is based on twice-daily dosing.1

Don't let TD
HOLD YOU BACK

Do you or a loved one have a TD diagnosis?

Don't let TD
HOLD YOU BACK

Are you or your loved one taking AUSTEDO XR?

Nearly 9 out of
10 people are satisfied with AUSTEDO XR7,‡

Based on a survey analysis from 131 people on AUSTEDO XR.7

Rebecca's partnership with her healthcare provider made it possible to diagnose her with TD and treat it with AUSTEDO

I didn't notice these things were related to a condition that was treatable. I just noticed I started having difficulty with simple tasks like cutting or buttoning, zippering, counting change.

Rebecca, living with TD

Individual results may vary.

Getting started is easy

With Teva Shared Solutions®, you have
options for
starting AUSTEDO XR. Sign up
and get support.

Enroll now

Get the conversation going

Whether you’re ready to talk to your doctor about
involuntary movements or still trying to figure out what to say, we have
an Appointment Preparation Guide to help you
start the conversation.

Start your guide

References:

1. AUSTEDO XR® (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604.

3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. December 2016.

4. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. May 2015.

5. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999.

6. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. September 2020.

7. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. August 2024.

Allyable tool icon